Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022568 (keratitis)
 5,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pretreatment of human fibroblast cultures with human leukocyte interferon (HIF, 1,000 IU/ml) resulted in a 24-h delay of virus replication after infection with vaccinia virus and herpes simplex virus type 1 and type 2. Additional HIF treatment 24 h after infection effectively lowered the maximum yield of viral infectivity. Equal results were obtained in simian cells with 3,000 IU of HIF per ml. The spread of two cell-bound herpesviruses, varicella zoster virus and Medical Lake macaque herpesvirus, was inhibited by 2,000 IU of HIF per ml in human fibroblasts and Vero cells, respectively. Varicella zoster virus infectivity was notably reduced by HIF, whereas the latter system showed a low sensitivity. To study the effect of HIF in the infected cornea, keratitis was induced experimentally in both eyes of 12 rhesus monkeys and 12 African green monkeys by inoculation with vaccinia virus and herpes simplex virus, respectively. In each monkey one eye served as a control for the full cycle of disease. In the other eye HIF treatment was initiated prophylactically 15 h before or simultaneously with the challenge virus infection or 6 to 20 h postinfectionally or therapeutically after onset of the disease, and the treatment was continued for 2 to 7 days. Prophylactic and simultaneous administration equally resulted in inhibition of both vaccinia and herpes keratitis. Postinfectional and therapeutic administration of interferon moderated the course of keratitis slightly and shortened the period of virus shedding.
 ...
PMID:Effect of human leukocyte interferon on vaccinia-and herpes virus-infected cell cultures and monkey corneas. 16 24

Previous results obtained in experimental and clinical trials have demonstrated that topical combined thrapy with human interferon (HI) and human colostral secretory immunoglobulin A (S-IgA) is effective against herpetic corneal infection. This therapy prevented encephalitis in rabbits but could not completely prevent recurrences either in rabbits or in patients. A number of in vitro studies were designed to elucidate the role of these factors in herpes simplex virus replication in the nervous system, with the following results: (1) HSV latency in trigeminal ganglia (TG) explanted from rabbits with experimental herpetic keratitis, topically treated with HI or HI/S-IgA: HSV was recovered in 30% TG after 15-19 days co-cultivation on RK-13 cells. (2) HSV replication in nervous ganglia and nerve of newborn rabbits in organ culture; influence of HI or HI plus IgG: a restrictive HSV productive infection was demonstrated in this system, although yields were always higher in nerve cultures. We were unable to demonstrate a direct effect of HI on HSV-1 replication. When explants were treated with HI and IgG before and after infection for 48 hours a delay in the expression of HSV-1 was detected by co-cultivation. (3) Replication of HSV-1 and HSV-2 in a C1300 murine neuroblastoma clone (NB41A3): both HSV types replicated with titres of 10(3.4) for HSV-1 AND 10(4.8) for HSV-2 at 48 hours p.i.; CPE was more marked for HSV-2 at 24 hours. HSV-specific antigens were demonstrated by the immunoperoxidase technique.
 ...
PMID:Interferon in the replication of herpes simplex virus in normal and pathological nerve cells. 22 73

In a controlled clinical study, 42 patients with dendritic keratitis were treated either with thermocautery plus human leukocyte interferon (HLI) or with minimal wiping debridement plus HLI. The results show that the efficiency with which primary debridement was carried out, determined the success of further therapy using interferon. We conclude that interferon works basically as a prophylactic agent and needs the support of further antiviral measures to be effective against dendritic keratitis.
 ...
PMID:Role of debridement and interferon in the treatment of dendritic keratitis. 30 83

Thirty-eight patients with virologically proven dendritic keratitis were treated using either debridement plus human leukocyte interferon (HLI) or debridement plus human fibroblast interferon (HFI) in a randomized, double-blind study. We administered one drop of HLI or HFI (1 X 10(6) reference units/ml) daily and found no significant difference in the action of either type of interferon.
 ...
PMID:Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. 31 Feb 69

The topical action of a combined therapy of human interferon (3000 U/ml) and secretory immunoglobulin IgA (1,5 mg/ml) was studied in 56 patients with herpetic keratitis. The pain and photophobia disappeared within 48 h after the beginning of treatment and a marked reduction of the corneal lesion during the first week of treatment was observed in all the patients. The therapy was effective, with complete healing of the lesion in 94.8% of cases; 72.2% of them healed in less than 15 days. The highest frequency of healing was between 5 and 10 days, and the rest up to 30 days. Humoral, immunological and delayed hypersensitivity studies were carried out in 36 patients.
 ...
PMID:Combined therapy of human interferon (HI) and secretory immunoglobulin (S-IgA) in the treatment of human herpetic keratitis. 35 19

The prophylactic potency of topically applied human leukocyte interferon and human fibroblast interferon was compared in a monkey model with herpes simplex virus type 1-induced keratitis. Both interferons effectively prevented keratitis at 1.9 X 10(6) U of activity per ml but were ineffective at 1.9 X 10(3) U/ml. Slight differences between human leukocyte interferon and human fibroblast interferon observed at the level of 1.9 X 10(5) U/ml were not statistically significant.
 ...
PMID:Comparative evaluation of human leukocyte and fibroblast interferon in the prevention of herpes simplex virus keratitis in a monkey model. 40 74

A double-blind clinical trial of human leukocyte interferon is in progress for assessment of the effect of this substance on recurrences of herpetic keratitis. Although human leukocyte interferon is highly effective in preventing infection in owl monkeys (protection from infection and prevention of recurrences correlate well in lower animals), there is no difference between the frequency of recurrences in placebo-treated patients and that in interferon-treated patients. Forty-nine patients have been treated with interferon, and 46 have received placebo; there have been seven recurrences (with herpes simplex virus isolated) in each group. The interferon used is highly stable both in storage in the laboratory and in clinical use. Because the titer of interferon in this study (6.4 X 10(4) units/ml) may be too low to accomplish our prophylactic needs, attempts are being made to use the material in more concentrated form.
 ...
PMID:Human leukocyte interferon for the prevention of recurrences of herpetic keratitis. 81 96

An open trial suggested that monkey interferon had a therapeutic effect on ulcerative vaccinial keratitis in humans. A randomized, double-blind, placebo-controlled trial of either monkey interferon or drops of idoxuridine (given hourly by day and at 2-hr intervals by night for three days) suggested a therapeutic effect from idoxuridine but not from monkey interferon. Results of experiments with rabbits suggested that a daily application of human interferon (1.1 X 10(7) international units/ml) would be effective in the prevention of herpetic ulcers but might not affect established lesions. Preliminary results are encouraging in a placebo-controlled, randomized trial of human interferon given once daily for seven days for prevention of recrudescence of epithelial herpetic lesions after minimal wiping debridement with a cotton-tipped swab. The design of the trial is closely analogous to that of the experiments with rabbits and permits ethically acceptable, placebo-controlled trials of antiviral agents.
 ...
PMID:Clinical trials of topical interferon therapy of ulcerative viral keratitis. 81 97

The 50% infectious dose of a preparation of herpes simplex virus was measured in eyes of rabbits by a multiple corneal inoculation method. One hour after inoculation of virus, one eye was treated with drops of human leukocyte interferon, and the other was treated with saline or with a different dose of interferon. Results from groups of three to four rabbits were combined for analysis. Treatment reduced the 50% infectious dose of virus in proportion to the concentration of interferon applied (within the range of 6.5 X 10(4)-1.3 X 10(6) units/ml) and not according to the total number of units instilled. Different treatment schedules were tried. Two applications of interferon each day were as effective as eight applications at intervals of 15 min or 1 hr. One application produced near-maximal antiviral effects for 18-24 hr. Thus, in human herpetic keratitis, a single daily application of the most concentrated available preparation of human interferon might be the most efficient schedule of treatment.
 ...
PMID:Optimal schedules for use of interferon in the corneas of rabbits with herpes simplex keratitis. 93

This critical review is based upon controlled experimental and clinical data. Dendritic keratitis initially should be treated by debridement of the diseased epithelium followed by antiviral medication. The advantages and disadvantages of different debridement techniques and different synthetic antivirals are discussed. Rational treatment of other forms of herpetic eye disease with antivirals, steroids, therapeutic soft lenses, collagenase inhibitors etc. necessitates first of all an exact diagnosis (disciform edema, interstitial herpetic keratitis, herpetic (kerato-)uveitis, metaherpetic erosion, metaherpetic ulcer). Therapeutic or prophylactic measures which as yet have found no valid experimental or clinical basis are discussed as well as further developments. Special interest is laid upon the application of human interferon.
 ...
PMID:[Herpes therapy and prophylaxis. I. A critical review (author's transl)]. 100 22


1 2 3 4 5 6 7 8 9 Next >>